文献速递前列腺癌

机器人根治性前列腺切除术治疗PSA筛查发现的前列腺癌的15年生化失败、转移、挽救治疗及癌症特异性和总生存率

15-year biochemical failure, metastasis, salvage therapy, and cancer-specific and overall survival rates in men treated with robotic radical prostatectomy for PSA-screen detected prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-05-04

该研究对2001至2005年间接受机器人辅助腹腔镜前列腺切除术的1807例临床局限性前列腺癌患者进行前瞻性随访至2020年,中位随访14.1年。15年生化失败率28.1%、转移率4.0%、二次治疗使用率16.3%、前列腺癌特异性死亡率2.5%、总生存率82.1%,且肿瘤学失败率随D'Amico术前和Diaz术后风险评分升高而增加。

要点

  • 15年生化失败率28.1%、转移率4.0%、前列腺癌特异性死亡率2.5%、总生存率82.1%。
  • D'Amico低、中、高危组15年生化失败率分别为15.2%、38.3%、44.1%。
  • Diaz风险评分1至5组15年生化失败率从5.5%升至89.2%。

核心结论

  • 在同期PSA筛查时代诊断为临床局限性前列腺癌并接受机器人辅助腹腔镜前列腺切除术的男性可获得持久的长期肿瘤学控制。
  • 本文按风险分层报告的数据是机器人根治性前列腺切除术后最长的随访数据,在向患者咨询机器人辅助腹腔镜前列腺切除术的预期肿瘤学结局时应具有价值。

研究设计与样本

  • 研究纳入2001年至2005年间接受机器人辅助腹腔镜前列腺切除术的1807例临床局限性前列腺癌男性,前瞻性收集随访数据至2020年。
  • 采用Kaplan-Meier法和竞争风险累积发生率法分析生化失败、转移进展、二次治疗使用、前列腺癌特异性死亡和总生存率。

主要发现

  • 中位随访14.1年,608例和312例男性分别为D'Amico中危和高危疾病。
  • 总体15年生化失败率28.1%、转移率4.0%、二次治疗使用率16.3%、前列腺癌特异性死亡率2.5%、总生存率82.1%。
  • D'Amico低、中、高危组15年生化失败率分别为15.2%、38.3%、44.1%,转移率分别为1.1%、4.1%、13.0%,前列腺癌特异性死亡率分别为0.5%、3.4%、6.6%。
  • Diaz风险评分1、2、3、4、5组15年生化失败率分别为5.5%、20.6%、41.8%、66.9%、89.2%,转移率分别为0%、0.5%、3.2%、20.5%、60.0%,前列腺癌特异性死亡率分别为0%、0.8%、0.6%、13.5%、37.5%。
  • D'Amico低至高危组15年总生存率分别为85.9%、78.6%、75.2%,Diaz评分1至5组分别为89.4%、83.2%、80.6%、67.2%、23.4%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An informed decision regarding a treatment option requires data on its long-term efficacy and side-effect profile. While the side-effects of robotic radical prostatectomy have been well-quantified, the data on its long-term efficacy are lacking. We here provide 15-year oncological outcomes of clinically-localized prostate cancer (CLPCa) patients treated with robot-assisted laparoscopic prostatectomy (RALP). METHODS: We treated 1,807 men with CLPCa with RALP between 2001 and 2005 and prospectively collected follow-up data through 2020. We examined the rates of biochemical failure (BCF), metastatic progression, secondary therapy use, PCa-specific mortality (PCSM), and overall survival (OS) using Kaplan-Meier and competing-risk cumulative incidence methods as appropriate. RESULTS: The median follow-up was 14.1 years. Six hundred eight and 312 men had D'Amico intermediate- and high-risk disease, respectively. Overall, the 15-year rates of BCF, metastasis, secondary therapy use, PCSM, and OS were 28.1%, 4.0%, 16.3%, 2.5%, and 82.1%, respectively. The rates of oncologic failure increased with increasing D'Amico (preoperative) and Diaz (postoperative) risk scores - BCF, metastasis, and PCSM rates in D'Amico low-, intermediate-, and high-risk groups at 15-years were 15.2%, 38.3%, and 44.1% [BCF], 1.1%, 4.1%, and 13.0% [metastasis], and 0.5%, 3.4%, and 6.6% [PCSM], respectively, and in Diaz risk groups 1, 2, 3, 4, and 5 were 5.5%, 20.6%, 41.8%, 66.9%, and 89.2% [BCF], 0%, 0.5%, 3.2%, 20.5%, and 60.0% [metastasis], and 0%, 0.8%, 0.6%, 13.5%, and 37.5% [PCSM], respectively. The OS rates in D'Amico low-to-high and Diaz 1-to-5 risk groups at 15-years were 85.9%, 78.6%, and 75.2%, and 89.4%, 83.2%, 80.6%, 67.2%, and 23.4%, respectively. CONCLUSIONS: Men diagnosed with clinically-localized prostate cancer in the contemporaneous PSA-screening era and treated with RALP achieve durable long-term oncological control. The data reported here (in a risk-stratified manner) represent the longest follow-up after robotic radical prostatectomy, and as such, should be of value when counseling patients regarding expected oncologic outcomes from RALP.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Sood A, Grauer R, Diaz-Insua M, et al. 15-year biochemical failure, metastasis, salvage therapy, and cancer-specific and overall survival rates in men treated with robotic radical prostatectomy for PSA-screen detected prostate cancer. Prostate Cancer Prostatic Dis. 2023. PMID: 37142635. doi:10.1038/s41391-023-00674-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。